• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Lyell Immunopharma Inc.

    2/14/22 4:17:18 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LYEL alert in real time by email
    SC 13G 1 d35843dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    LYELL IMMUNOPHARMA, INC.

    (Name of Issuer)

    COMMON STOCK, $0.0001 PAR VALUE

    (Title of Class of Securities)

    55083R104

    (CUSIP Number)

    DECEMBER 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 55083R104    13G    Page 2 of 6 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

      MWG Management Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      20,162,332

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      20,162,332

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      20,162,332

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.38%

    12.  

      TYPE OF REPORTING PERSON

     

      CO


    CUSIP No. 55083R104    13G    Page 3 of 6 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Milky Way Investments Group Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      20,162,332

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      20,162,332

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      20,162,332

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.38%

    12.  

      TYPE OF REPORTING PERSON

     

      CO


    CUSIP No. 55083R104    13G    Page 4 of 6 Pages

     

    Item 1(a).

    Name of Issuer:

    Lyell Immunopharma, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    201 Haskins Way

    South San Francisco, California

     

    Item 2.

     

    (a) – (c)

    Name of Persons Filing; Address; Citizenship

    This statement on Schedule 13(G) is being filed jointly by the following persons, collectively, the “Reporting Persons”:

     

      i.

    MWG Management Limited

    Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands

    Citizenship: British Virgin Islands

     

      ii.

    Milky Way Investments Group Limited

    Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands

    Citizenship: British Virgin Islands

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    55083R104

     

    Item 3.

    Not applicable

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 240,471,497 shares of Common Stock outstanding as of November 12, 2021, as reported by the Issuer in its 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

    Milky Way Investments Group Limited is controlled by MWG Management Limited, its corporate director.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.


    CUSIP No. 55083R104    13G    Page 5 of 6 Pages

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 55083R104    13G    Page 6 of 6 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    MWG MANAGEMENT LIMITED

    /s/ Nicholas Lane

    Name:   Nicholas Lane
    Title:   President
    MILKY WAY INVESTMENTS
    GROUP LIMITED

    /s/ Despoina Zinonos

    Name:   Despoina Zinonos
    Title:   President
    Get the next $LYEL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LYEL

    DatePrice TargetRatingAnalyst
    10/30/2024$6.00 → $1.00Buy → Underperform
    BofA Securities
    6/27/2024$6.00 → $1.00Buy → Neutral
    H.C. Wainwright
    8/28/2023$15.00 → $5.00Overweight → Neutral
    JP Morgan
    11/14/2022$15.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2022$13.00 → $7.00Buy → Neutral
    Goldman
    10/17/2022$12.00Buy
    H.C. Wainwright
    1/6/2022$25.00 → $20.00Overweight
    Morgan Stanley
    7/12/2021$25.00Buy
    BofA Securities
    More analyst ratings

    $LYEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lyell Immunopharma downgraded by BofA Securities with a new price target

      BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously

      10/30/24 6:29:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously

      6/27/24 7:49:16 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma downgraded by JP Morgan with a new price target

      JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously

      8/28/23 7:19:05 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series

      SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright "HCW@Home" Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently presented in an oral session at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on LYL314, Lyell's lead product candidate, and the emerging landscape of next-generation dual targeting chimeric antigen

      6/23/25 5:00:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

      LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line settingLyell to host an investor webcast at 8:00 AM ET today SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunoph

      6/17/25 6:30:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

      Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate

      6/9/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    SEC Filings

    See more
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      6/26/25 4:07:08 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      6/17/25 8:49:17 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Lyell Immunopharma Inc.

      8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

      6/9/25 4:23:34 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bachleda Mark

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:48:27 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Meltz Mark A

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:47:11 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Shook David was granted 21,900 shares (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      6/11/25 5:45:48 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      4/2/25 3:46:01 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramachandra Sumant bought $115,220 worth of shares (200,000 units at $0.58) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      3/25/25 6:46:17 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Klausner Richard bought $94,942 worth of shares (158,000 units at $0.60) (SEC Form 4)

      4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

      3/18/25 8:07:51 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

      Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate

      6/9/25 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

      Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues

      8/8/23 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

      SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl

      7/5/23 4:05:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Financials

    Live finance-specific insights

    See more
    • Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

      LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line settingLyell to host an investor webcast at 8:00 AM ET today SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunoph

      6/17/25 6:30:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

      Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programsCash runway following the close of the transaction is expected to fund operations into 2027, through impor

      10/24/24 4:00:00 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

      Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple

      6/26/24 7:00:00 AM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LYEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

      SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

      11/12/24 4:04:21 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

      SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

      11/4/24 1:30:41 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Lyell Immunopharma Inc.

      SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)

      10/31/24 6:00:17 PM ET
      $LYEL
      Biotechnology: Pharmaceutical Preparations
      Health Care